Phospho-CDC25A (Ser178) Antibody

What is CDC25A and what is its role in cell cycle regulation?

CDC25A belongs to the CDC25 family of phosphatases, which includes three members in human cells: CDC25A, CDC25B, and CDC25C. Each functions at different phases of the cell cycle, with CDC25A specifically required for progression through G1 and S phases. CDC25A acts as a dual-specificity phosphatase that activates cyclin-dependent kinase CDC2 by removing inhibitory phosphate groups. This activation is a critical event for cell cycle progression. CDC25A is classified as an oncogene, although its precise mechanisms in oncogenesis remain under investigation. In normal cells, CDC25A is specifically degraded in response to DNA damage, which prevents cells with chromosomal abnormalities from progressing through cell division, thus functioning as an important checkpoint mechanism .

Why is the phosphorylation of CDC25A at Serine 178 biologically significant?

Phosphorylation of CDC25A at Serine 178 represents a critical post-translational modification that regulates protein stability and function. Research indicates that phosphorylation at Ser178, along with other sites (Ser-76, Ser-124, Ser-279, and Ser-293), promotes ubiquitin-dependent proteolysis of CDC25A by the SCF complex . This regulated degradation is essential for cell cycle control, particularly in response to DNA damage or replication stress. The phosphorylation status at Ser178 thus serves as a molecular switch that helps determine whether cells continue to proliferate or halt division in response to cellular stresses. This phosphorylation site is conserved across human, mouse, and rat CDC25A proteins, highlighting its evolutionary importance in cell cycle regulation .

What are the optimal applications for Phospho-CDC25A (Ser178) antibody?

The Phospho-CDC25A (Ser178) antibody has been validated for several key applications in molecular and cellular biology research. Western blotting (WB) is the primary application, with recommended dilutions of 1:500-1:1000. This application is ideal for detecting the phosphorylated form of CDC25A in cell or tissue lysates. The antibody is also suitable for immunohistochemistry (IHC) with paraffin-embedded sections, enabling visualization of phosphorylated CDC25A in tissue contexts. Additionally, the antibody can be used for enzyme-linked immunosorbent assay (ELISA) at a recommended dilution of 1:20000, and some product variants are validated for immunocytochemistry (ICC). These applications collectively enable researchers to examine phospho-CDC25A expression and localization across multiple experimental systems .

What is the specificity profile of Phospho-CDC25A (Ser178) antibody?

The Phospho-CDC25A (Ser178) antibody specifically detects endogenous levels of CDC25A only when phosphorylated at Serine 178, making it a valuable tool for studying this specific post-translational modification. The antibody shows cross-reactivity across human, mouse, and rat samples, reflecting the conserved nature of this phosphorylation site across mammalian species. The antibody is generated using a synthetic peptide derived from human CDC25A corresponding to amino acid residues around the phosphorylated Ser178 (approximately amino acids 144-193). This specificity allows researchers to distinguish between phosphorylated and non-phosphorylated forms of CDC25A, enabling detailed studies of CDC25A regulation in different physiological and pathological conditions .

What are the proper storage and handling recommendations for maintaining antibody activity?

To maintain optimal antibody activity, the Phospho-CDC25A (Ser178) antibody should be shipped at 4°C. Upon delivery, it is recommended to aliquot the antibody and store at -20°C to minimize freeze-thaw cycles, which can degrade antibody quality. The antibody is typically supplied in a buffer containing phosphate-buffered saline (PBS) without Mg²⁺ and Ca²⁺, pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol. This formulation helps maintain antibody stability during storage. It is critical to avoid repeated freeze-thaw cycles as these can compromise antibody binding efficiency and specificity. For long-term storage projects, creating multiple small aliquots is strongly recommended to preserve antibody performance across multiple experiments .

How should I design experiments to distinguish between different phosphorylated forms of CDC25A?

Designing experiments to distinguish between different phosphorylated forms of CDC25A requires a multi-faceted approach. First, utilize phospho-specific antibodies that target distinct sites (such as Ser82, Ser178) in parallel experiments. When analyzing by Western blot, consider incorporating lambda phosphatase treatment as a control to confirm the phospho-specificity of the observed bands. For more detailed analysis, employ two-dimensional gel electrophoresis to separate CDC25A based on both molecular weight and isoelectric point, which can resolve different phosphorylated species. Mass spectrometry analysis represents the gold standard for comprehensive phosphorylation profiling, as evidenced by studies identifying multiple CDC25A phosphorylation sites (S18, S107, S156, S185, S283, S320, and S321) . Additionally, generating non-phosphorylatable mutants (serine to alanine) and phosphomimetic mutants (serine to glutamic acid) for functional studies can help establish the biological significance of specific phosphorylation events. This integrated approach enables robust analysis of CDC25A phosphorylation status across different experimental conditions .

What controls should be included when using Phospho-CDC25A (Ser178) antibody?

Rigorous experimental design with appropriate controls is essential when using the Phospho-CDC25A (Ser178) antibody. Positive controls should include cell lines or tissues known to express phosphorylated CDC25A at Ser178, such as proliferating cells or cells treated with agents that induce CDC25A phosphorylation (e.g., certain kinase activators). Negative controls should include samples where the phosphorylation is expected to be absent, such as cells treated with phosphatase or specific kinase inhibitors. Include a blocking peptide control, using the immunizing phosphopeptide to confirm antibody specificity. For Western blotting applications, loading controls like GAPDH or β-actin are essential for normalization. Additionally, isotype controls (e.g., rabbit IgG, such as A82272 or A17360) should be included, particularly for immunohistochemistry or immunofluorescence applications. For definitive validation, consider using CDC25A knockout or knockdown samples, or cells expressing non-phosphorylatable CDC25A-S178A mutants as specificity controls .

How can I use this antibody to study CDC25A degradation pathways?

The Phospho-CDC25A (Ser178) antibody offers a powerful tool for studying CDC25A degradation pathways, particularly since phosphorylation at Ser178 promotes ubiquitin-dependent proteolysis by the SCF complex. Design time-course experiments treating cells with proteasome inhibitors (e.g., MG132) to block degradation, then analyze phospho-CDC25A accumulation using the antibody. This approach helps distinguish between changes in phosphorylation versus changes in total protein levels. For studying degradation kinetics, perform cycloheximide chase assays, using the phospho-specific antibody alongside a total CDC25A antibody to compare degradation rates of phosphorylated versus total protein pools. To investigate specific degradation pathways, combine the antibody with co-immunoprecipitation experiments targeting components of the SCF complex or other potential E3 ubiquitin ligases. Additionally, manipulate cellular stress conditions (DNA damage, replication stress) to examine how these impact Ser178 phosphorylation and subsequent degradation, providing insight into regulatory mechanisms controlling CDC25A stability during different cellular states .

How can phospho-CDC25A (Ser178) antibody be used to investigate the DNA damage response?

The phospho-CDC25A (Ser178) antibody provides a valuable tool for investigating the DNA damage response pathway, as CDC25A degradation represents a critical checkpoint mechanism. Researchers can design experiments where cells are exposed to various DNA-damaging agents (UV radiation, ionizing radiation, chemotherapeutic drugs) and then monitor the kinetics of Ser178 phosphorylation using Western blotting or immunofluorescence with this antibody. Time-course experiments are particularly valuable, as they can reveal the temporal relationship between DNA damage, CDC25A phosphorylation, and subsequent cell cycle arrest. Co-immunostaining with DNA damage markers (such as γH2AX) and cell cycle indicators enables correlation between damage severity, phosphorylation status, and cell cycle position. For mechanistic studies, researchers can inhibit specific kinases implicated in the DNA damage response (Chk1, Chk2, ATM, ATR) to determine their contribution to Ser178 phosphorylation. This antibody can also be employed in chromatin immunoprecipitation experiments to investigate whether phosphorylated CDC25A associates with chromatin during the damage response, providing insights into its nuclear functions beyond phosphatase activity .

What is the relationship between CDC25A Ser178 phosphorylation and other phosphorylation sites?

CDC25A regulation involves a complex pattern of phosphorylation across multiple sites, with Ser178 representing just one component of this regulatory network. Research indicates that phosphorylation on Ser-76, Ser-124, Ser-178, Ser-279, and Ser-293 collectively promotes ubiquitin-dependent proteolysis via the SCF complex . Additional mass spectrometry studies have identified phosphorylation at S18, S107, S156, S185, S283, S320, and S321, including sites modified by DYRK2 kinase . To investigate the interplay between these sites, researchers should employ multiple phospho-specific antibodies in parallel experiments. Sequential or combinatorial mutations of phosphorylation sites can reveal whether these modifications operate hierarchically (with some sites serving as priming events for others) or cooperatively (requiring multiple sites for biological effect). Particular attention should be paid to whether Ser178 phosphorylation serves as a prerequisite for other modifications, or vice versa. Analytical techniques like Phos-tag gels, which can separate proteins based on phosphorylation status, allow visualization of differently phosphorylated CDC25A species. Mass spectrometry remains the definitive approach for comprehensive phosphorylation profiling, especially when combined with stable isotope labeling techniques .

How does CDC25A Ser178 phosphorylation status change during normal cell cycle progression?

The phosphorylation status of CDC25A at Ser178 exhibits dynamic changes throughout normal cell cycle progression, reflecting its regulatory role in cell cycle transitions. To characterize these changes, researchers should synchronize cells at different cell cycle phases (G1, S, G2, M) using methods such as serum starvation/stimulation, double thymidine block, or nocodazole treatment, followed by release. At defined time points, analyze Ser178 phosphorylation by Western blotting using the phospho-specific antibody, while simultaneously monitoring cell cycle position using flow cytometry with propidium iodide staining or markers like cyclin E (G1/S), cyclin A (S), and cyclin B (G2/M). Time-lapse microscopy with fluorescently tagged CDC25A in combination with immunostaining for the phospho-epitope can provide insights into the spatial and temporal dynamics of phosphorylation events. Additionally, researchers should investigate how phosphorylation status correlates with CDC25A enzymatic activity by performing phosphatase assays on immunoprecipitated CDC25A from cells at different cycle phases. These approaches collectively enable mapping of Ser178 phosphorylation patterns throughout the cell cycle and correlation with CDC25A function and localization .

What roles do different kinases play in CDC25A Ser178 phosphorylation?

Multiple kinases have been implicated in CDC25A phosphorylation, though the specific kinases targeting Ser178 require further characterization. To identify the responsible kinases, researchers should employ pharmacological inhibition and genetic approaches. Treat cells with specific inhibitors of candidate kinases (Chk1, Chk2, p38 MAPK, DYRK2, CK1, GSK3β) followed by Western blotting with the phospho-Ser178 antibody to assess impact on phosphorylation status. Complement this approach with knockdown/knockout studies of candidate kinases using siRNA, shRNA, or CRISPR-Cas9. In vitro kinase assays using purified kinases and recombinant CDC25A can directly assess which kinases are capable of phosphorylating Ser178. Given that DYRK2 has been shown to phosphorylate CDC25A at multiple sites , investigate whether it also targets Ser178. Sequential kinase reactions can reveal whether some kinases create priming phosphorylations that facilitate Ser178 phosphorylation by other kinases. Additionally, examine whether different cellular stresses (DNA damage, replication stress, oxidative stress) activate distinct kinases that target Ser178, potentially explaining context-dependent regulation of CDC25A .

What are common issues when detecting phospho-CDC25A (Ser178) by Western blotting and how can they be addressed?

Detecting phospho-CDC25A (Ser178) by Western blotting can present several challenges. First, ensure optimal sample preparation by using phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers to preserve phosphorylation status. CDC25A has a relatively short half-life, so proteasome inhibitors (MG132) may be needed to prevent degradation during sample preparation. For antibody dilution, start with the recommended range (1:500-1:1000) but optimize for your specific samples . If background is high, increase blocking time or try different blocking agents (5% BSA often works better than milk for phospho-epitopes). For weak signals, consider using enhanced chemiluminescence substrates with higher sensitivity or longer exposure times. If multiple bands appear, verify specificity using a blocking peptide or lambda phosphatase treatment. Since CDC25A levels fluctuate during the cell cycle, synchronizing cells can help obtain more consistent results. Additionally, CDC25A can undergo various post-translational modifications creating multiple bands; use a total CDC25A antibody in parallel to help interpret patterns. Finally, if detection remains challenging, enriching phosphoproteins using immunoprecipitation prior to Western blotting can improve sensitivity .

How should immunohistochemistry protocols be optimized for phospho-CDC25A (Ser178) detection in tissue samples?

Optimizing immunohistochemistry for phospho-CDC25A (Ser178) detection in tissues requires attention to several critical factors. First, tissue fixation is crucial—phospho-epitopes are sensitive to overfixation, so limit formalin fixation to 24 hours and use freshly cut sections when possible. Antigen retrieval is essential; try both heat-induced epitope retrieval (citrate buffer, pH 6.0) and enzymatic retrieval methods to determine optimal conditions. Blocking endogenous peroxidase activity is particularly important for phospho-epitopes, which can be sensitive to oxidation. During protocol optimization, test a range of antibody dilutions and incubation times (overnight at 4°C often yields better results than shorter incubations). Include positive control tissues with known phospho-CDC25A expression (proliferating tissues) and negative controls (both antibody omission and non-specific IgG controls). For validation, perform phosphatase treatment on serial sections to confirm signal specificity. When interpreting results, remember that phospho-CDC25A shows primarily nuclear localization during G1/S phase, so cytoplasmic staining may represent non-specific binding. Finally, consider using tyramide signal amplification systems for enhanced sensitivity, particularly in tissues with low CDC25A expression .

How can I verify the specificity of phospho-CDC25A (Ser178) antibody results in my experimental system?

Verifying antibody specificity is critical for confident interpretation of phospho-CDC25A (Ser178) results. Implement a multi-pronged validation approach beginning with phosphatase treatment—treat duplicate samples with lambda phosphatase prior to analysis to confirm that signal loss occurs when phosphorylation is removed. Generate or obtain expression constructs for wild-type CDC25A and a non-phosphorylatable S178A mutant; overexpression of wild-type should increase detectable signal while the S178A mutant should not be recognized by the phospho-specific antibody. For definitive validation, use CRISPR-Cas9 or siRNA to deplete endogenous CDC25A, confirming signal elimination. Peptide competition assays with the immunizing phosphopeptide provide another specificity control—pre-incubation of the antibody with the phosphopeptide should abolish specific signal. When possible, confirm results using alternative techniques or antibodies from different sources or clones that recognize the same phospho-epitope. Mass spectrometry analysis of immunoprecipitated protein can provide ultimate confirmation that the detected protein is indeed phosphorylated at Ser178. Always include biological controls, such as treatments known to increase (cell cycle progression) or decrease (certain phosphatase activators) CDC25A Ser178 phosphorylation .

How can phospho-CDC25A (Ser178) antibody be used in cancer research and potential therapeutic development?

The phospho-CDC25A (Ser178) antibody offers valuable applications in cancer research and therapeutic development. Researchers can use this antibody to profile Ser178 phosphorylation status across tumor samples and matched normal tissues, potentially identifying dysregulation patterns specific to certain cancer types. This approach may reveal whether altered Ser178 phosphorylation correlates with clinical outcomes, treatment response, or specific molecular subtypes. In drug discovery efforts, the antibody can be employed in high-throughput screening assays to identify compounds that modulate CDC25A phosphorylation, potentially targeting the kinases responsible for Ser178 phosphorylation. For personalized medicine applications, analyzing phospho-CDC25A levels in patient-derived xenografts or organoids may predict response to cell cycle-targeting therapies. The antibody can also be used to monitor pharmacodynamic responses during clinical trials of such therapies. Furthermore, combining phospho-CDC25A analysis with other cell cycle regulators could help develop composite biomarkers that more accurately predict cancer progression or treatment response than single markers alone .

What recent advances have been made in understanding the kinases that phosphorylate CDC25A at Ser178?

Recent research has expanded our understanding of the kinase networks regulating CDC25A phosphorylation, though specific kinases targeting Ser178 continue to be characterized. Studies have identified DYRK2 as an important kinase that phosphorylates CDC25A at multiple sites, potentially including Ser178 . This finding suggests a regulatory mechanism where DYRK2 acts as a master regulator of CDC25A stability. The functional significance of these phosphorylation events has been demonstrated through the generation of non-phosphorylatable mutants (serine to alanine) for various sites, including S18, S107, S156, S185, S283, S320, and S321 . Beyond DYRK2, checkpoint kinases (Chk1/Chk2) have been implicated in CDC25A regulation, particularly in response to DNA damage. Understanding the complex interplay between these kinases and how they respond to different cellular stresses remains an active research area. Advances in proteomics and kinase-substrate prediction algorithms continue to refine our knowledge of the kinase-phosphatase networks controlling CDC25A function. These insights may eventually lead to more targeted therapeutic approaches for cancer and other proliferative disorders .

How might single-cell analysis techniques be combined with phospho-CDC25A detection to advance cell cycle research?

Integrating single-cell analysis with phospho-CDC25A detection represents a frontier in cell cycle research with significant potential. Researchers can combine phospho-specific flow cytometry using the Ser178 antibody with DNA content analysis to correlate phosphorylation status with precise cell cycle position at the single-cell level. This approach overcomes limitations of population-based analyses that mask cell-to-cell variability. Mass cytometry (CyTOF) allows simultaneous detection of multiple phospho-epitopes, enabling comprehensive profiling of CDC25A phosphorylation alongside other cell cycle regulators within individual cells. Single-cell RNA-seq paired with antibody-based protein detection (CITE-seq) can correlate CDC25A phosphorylation status with transcriptional programs at single-cell resolution. For spatial information, imaging mass cytometry or multiplexed immunofluorescence enables visualization of phospho-CDC25A localization relative to other cellular structures and proteins. Live-cell imaging with genetically encoded biosensors for CDC25A phosphorylation could provide unprecedented temporal resolution of phosphorylation dynamics. These techniques collectively offer new avenues to understand how heterogeneity in CDC25A phosphorylation contributes to cell fate decisions and how this regulation may be disrupted in disease states .